HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of
— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease...
Source: globenewswire.com
Fruquintinib Development Beyond News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Fruquintinib Development Beyond. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Fruquintinib Development Beyond Today - Breaking & Trending Today
HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global
— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall...
Source: globenewswire.com
Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: HUTCHMED Completes Planned Enrollment of FRESCO-2
Investegate announcements from Hutchmed China Ltd, HUTCHMED Completes Planned Enrollment of FRESCO-2
Source: investegate.co.uk